Malignant Glioma clinical trials

Explore recruiting malignant glioma clinical trials.

Recruiting malignant glioma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Malignant Glioma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized phase III trial with lomustine versus lomustine and bevacizumab for patients with recurrent glioblastoma

Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Oxidative Phosphorylation Targeting In Malignant glioma Using Metformin plus radiotherapy temozolomide

France

Therapeutic exploratory (Phase II) EU CTIS Study details

FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors

Denmark, Netherlands, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study (The ACTION Study)

Netherlands, Germany, Italy, Spain, Denmark, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

Germany, Belgium, Denmark, Spain, France, Ireland +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

BORTEZOMIB SENSITIZATION OF RECURRENT GRADE-4 GLIOMA WITH UNMETHYLATED MGMT PROMOTER TO TEMOZOLOMIDE. PHASE IB/II. (BORTEM 17)

Norway

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Malignant Glioma trials by city

Malignant Glioma in Toronto Malignant Glioma in Vancouver Malignant Glioma in Montreal Malignant Glioma in Calgary Malignant Glioma in Edmonton Malignant Glioma in Ottawa Malignant Glioma in Winnipeg Malignant Glioma in Quebec City Malignant Glioma in Hamilton Malignant Glioma in Kitchener Malignant Glioma in London Malignant Glioma in Halifax Malignant Glioma in New York Malignant Glioma in Los Angeles Malignant Glioma in Chicago Malignant Glioma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease